Success Metrics

Clinical Success Rate
59.4%

Based on 19 completed trials

Completion Rate
59%(19/32)
Active Trials
20(33%)
Results Posted
84%(16 trials)
Terminated
13(22%)

Phase Distribution

Ph not_applicable
13
22%
Ph phase_2
20
33%
Ph early_phase_1
1
2%
Ph phase_1
9
15%

Phase Distribution

10

Early Stage

20

Mid Stage

0

Late Stage

Phase Distribution43 total trials
Early Phase 1First-in-human
1(2.3%)
Phase 1Safety & dosage
9(20.9%)
Phase 2Efficacy & side effects
20(46.5%)
N/ANon-phased studies
13(30.2%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

55.9%

19 of 34 finished

Non-Completion Rate

44.1%

15 ended early

Currently Active

20

trials recruiting

Total Trials

60

all time

Status Distribution
Active(21)
Completed(19)
Terminated(15)
Other(5)

Detailed Status

Completed19
Terminated13
Recruiting13
Active, not recruiting7
unknown5
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
60
Active
20
Success Rate
59.4%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (2.3%)
Phase 19 (20.9%)
Phase 220 (46.5%)
N/A13 (30.2%)

Trials by Status

terminated1322%
not_yet_recruiting12%
active_not_recruiting712%
recruiting1322%
unknown58%
completed1932%
withdrawn23%

Recent Activity

Clinical Trials (60)

Showing 20 of 60 trialsScroll for more
NCT04331041Phase 2

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Active Not Recruiting
NCT04331067Phase 1

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Active Not Recruiting
NCT06065358Not Applicable

Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction

Active Not Recruiting
NCT03389477Phase 2

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Active Not Recruiting
NCT07145177Phase 1

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Recruiting
NCT05435495

Mechanisms of Resistance to PSMA Radioligand Therapy

Recruiting
NCT07217496Phase 1

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Withdrawn
NCT05024175

Long-term Follow-up of Subjects Treated With CAR T Cells

Recruiting
NCT05286827Phase 2

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Terminated
NCT07447076Phase 2

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

Not Yet Recruiting
NCT07233928Not Applicable

Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers

Recruiting
NCT06865677Phase 2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated
NCT04067115Phase 1

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

Completed
NCT06611072Not Applicable

OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study

Recruiting
NCT03449901Phase 2

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

Completed
NCT01723774Phase 2

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active Not Recruiting
NCT01771458Phase 2

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

Completed
NCT04896073Phase 2

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

Completed
NCT02554565Not Applicable

Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV)

Terminated
NCT05009979Phase 2

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Terminated

Drug Details

Intervention Type
PROCEDURE
Total Trials
60